Related:
On August 27 Idenix: Places IDX19368 on Clinical Hold
A clinical hold was placed on IDX19368, after the FDA verbally informed Idenix of concerns related to serious heart issues seen in Bristol-Myers - BMS-986094. On August 23 Bristol-Myers discontinued the phase II trial after one patient died, also nine patients were hospitalized and two remained hospitalized.
Released Today
BRIEF-Idenix Pharma says got FDA letter on hepatitis C product IDX19368
BRIEF-Idenix Pharma says got FDA letter on hepatitis C product IDX19368
Sept 20 (Reuters) - Idenix
Pharmaceuticals Inc :
* Says received formal FDA letter
related to IDX19368 - SEC filing
* Says FDA requested additional
toxicology and metabolism preclinical studies on IDX19368
((Bangalore Equities Newsroom; +91
80 4135 5800; within U.S. +1 646 223 8780)) ((For more news, please click here
))
(C) Reuters 2012. All rights reserved. Republication
or redistribution of Reuters content, including by caching, framing or similar
means, is expressly prohibited without the prior written consent of
Reuters.
No comments:
Post a Comment